Inhibition of the BMP pathway alone and in combination with BCR-ABL significantly decreases the expression level of AVCR1 (ALK2) in CML-iPSCs. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.